Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
ND Trinklein, D Pham, U Schellenberger, B Buelow… - MAbs, 2019 - Taylor & Francis
ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
[引用][C] Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
ND Trinklein, D Pham, U Schellenberger, B Buelow… - mAbs, 2019 - cir.nii.ac.jp
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific
antibodies | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
antibodies | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
ND Trinklein, D Pham, U Schellenberger, B Buelow… - Mabs, 2019 - europepmc.org
ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
[PDF][PDF] Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
ND Trinklein, D Pham, U Schellenberger, B Buelow… - 2019 - scienceopen.com
ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
ND Trinklein, D Pham, U Schellenberger… - …, 2019 - pubmed.ncbi.nlm.nih.gov
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in
humans, but cytokine release-related toxicities have affected their clinical utility. The use of …
humans, but cytokine release-related toxicities have affected their clinical utility. The use of …
[HTML][HTML] Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
ND Trinklein, D Pham, U Schellenberger, B Buelow… - mAbs, 2019 - ncbi.nlm.nih.gov
ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
ND Trinklein, D Pham, U Schellenberger, B Buelow… - Mabs, 2019 - europepmc.org
ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
activity in humans, but cytokine release-related toxicities have affected their clinical utility …